Flamel Technologies (NASDAQ: FLML) announced the results of a First-in-Man (FIM) clinical study in healthy volunteers using its proprietary LiquiTime ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE